Author

N. Khalasawi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1 Assay:proteomics· 1

Frequent Co-Authors

A. A. Desai· 1 shared A. Hans· 1 shared A. Miller· 1 shared C. Yin· 1 shared D. Ozog· 1 shared E. L. Yao· 1 shared G. Vellaichamy· 1 shared H. Lim· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

A. A. Desai

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Facile generation of biepitopic antibodies with intrinsic agonism for activating receptors in the tumor necrosis factor superfamily

H. S. Jhajj, J. S. Schardt, N. Khalasawi, E. L. Yao, T. S. Lwo, N.-Y. Kwon, R. L. O'Meara, A. A. Desai, P. M. Tessier

This paper describes a method to generate biepitopic antibodies that activate TNF receptors by combining single-chain antibodies with IgG light chains, enhancing agonist activity without animal immunization.

bioRxiv · Dec 11, 2023Bioengineering

Mass cytometry identifies dysregulation of circulating and cutaneous immune cells in patients with hidradenitis suppurativa

P. Dimitrion, I. Hamzavi, C. Yin, I. Loveless, J. Toor, K. Subedi, N. Khalasawi, A. Miller, R. Huggins, I. Adrianto, J. Veenstra, G. Vellaichamy, A. Hans, S. Daveluy, M. Athar, , Q.-S. Mi

This study identifies immune cell dysregulation in hidradenitis suppurativa using mass cytometry and RNA-seq, finding increased CD38 expression in monocytes and suggesting CD38 as a therapeutic target.

bioRxiv · Jan 27, 2023 · PreprintImmunology